NASDAQ:PRPH ProPhase Labs (PRPH) Stock Price, News & Analysis → Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It! (From American Alternative) (Ad) Free PRPH Stock Alerts $5.06 -0.10 (-1.94%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$5.05▼$5.4650-Day Range$4.47▼$7.3552-Week Range$4.05▼$9.94Volume15,554 shsAverage Volume46,003 shsMarket Capitalization$91.33 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ProPhase Labs alerts: Email Address ProPhase Labs MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside117.4% Upside$11.00 Price TargetShort InterestBearish1.83% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.96 out of 5 starsMedical Sector559th out of 907 stocksPharmaceutical Preparations Industry255th out of 419 stocks 3.5 Analyst's Opinion Consensus RatingProPhase Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageProPhase Labs has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.83% of the float of ProPhase Labs has been sold short.Short Interest Ratio / Days to CoverProPhase Labs has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in ProPhase Labs has recently increased by 3.67%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldProPhase Labs does not currently pay a dividend.Dividend GrowthProPhase Labs does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRPH. Previous Next 3.6 News and Social Media Coverage News SentimentProPhase Labs has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for ProPhase Labs this week, compared to 1 article on an average week.Search Interest5 people have searched for PRPH on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added ProPhase Labs to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProPhase Labs insiders have not sold or bought any company stock.Percentage Held by Insiders26.10% of the stock of ProPhase Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.45% of the stock of ProPhase Labs is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of ProPhase Labs is -5.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProPhase Labs is -5.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProPhase Labs has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad American AlternativeUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...CLICK HERE TO GET YOUR GUIDE NOW About ProPhase Labs Stock (NASDAQ:PRPH)ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It also offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Read More PRPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRPH Stock News HeadlinesApril 25, 2024 | americanbankingnews.comProPhase Labs, Inc. (NASDAQ:PRPH) to Post Q1 2025 Earnings of $0.10 Per Share, Diamond Equity ForecastsApril 23, 2024 | americanbankingnews.comProPhase Labs (NASDAQ:PRPH) Stock Price Crosses Above Two Hundred Day Moving Average of $5.00April 25, 2024 | Behind the Markets (Ad)Will this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!April 16, 2024 | marketwatch.comProPhase Labs Shares Jump on New AI-Based ProjectApril 16, 2024 | globenewswire.comProPhase Labs Unveils Project ZenQ-AIApril 10, 2024 | finanznachrichten.deProPhase Labs, Inc.: ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024April 10, 2024 | baystreet.caProPhase Flat on Cancer Drug ProgressApril 10, 2024 | globenewswire.comProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024April 25, 2024 | American Alternative (Ad)Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...April 1, 2024 | globenewswire.comProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | finance.yahoo.comProPhase Labs, Inc. (PRPH)March 18, 2024 | finance.yahoo.comProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | msn.comPRPH Stock Earnings: ProPhase Labs Misses EPS, Misses Revenue for Q4 2023March 15, 2024 | globenewswire.comProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic InitiativesMarch 14, 2024 | benzinga.comProPhase Labs's Earnings: A PreviewMarch 12, 2024 | msn.comDown 34% and 57%, Wall Street Says These 2 Stocks Will Gain 230%March 8, 2024 | globenewswire.comPROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024March 1, 2024 | finance.yahoo.comProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 29% Above Their Intrinsic Value EstimateFebruary 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Prophase Labs (PRPH) and Crispr Therapeutics AG (CRSP)February 21, 2024 | finance.yahoo.comDiamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)February 20, 2024 | finance.yahoo.comProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMARTFebruary 20, 2024 | finance.yahoo.comProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMARTFebruary 16, 2024 | finance.yahoo.comPRPH Mar 2024 5.000 putFebruary 15, 2024 | markets.businessinsider.comBuy Rating for Prophase Labs on Strong Clinical Trial Results and Manufacturing ExpansionFebruary 14, 2024 | finanznachrichten.deProPhase Labs, Inc.: ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement EquivirFebruary 14, 2024 | finance.yahoo.comProPhase Labs Announces Preliminary Positive Results for Dietary Supplement EquivirFebruary 14, 2024 | globenewswire.comProPhase Labs Announces Preliminary Positive Results for Dietary Supplement EquivirSee More Headlines Receive PRPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PRPH CUSIPN/A CIK868278 Webwww.prophaselabs.com Phone(215) 345-0919Fax215-345-5920Employees113Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+117.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,780,000.00 Net Margins-37.81% Pretax Margin-51.37% Return on Equity-29.83% Return on Assets-18.14% Debt Debt-to-Equity Ratio0.29 Current Ratio2.28 Quick Ratio2.10 Sales & Book Value Annual Sales$44.38 million Price / Sales2.06 Cash FlowN/A Price / Cash FlowN/A Book Value$2.74 per share Price / Book1.85Miscellaneous Outstanding Shares18,050,000Free Float13,335,000Market Cap$91.33 million OptionableOptionable Beta-0.29 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Ted William Karkus (Age 65)Chairman & CEO Comp: $902.2kMr. Jed A. Latkin (Age 50)Chief Operating Officer & Head of Finance Department Mr. Robert A. Morse Jr. (Age 49)Controller, Principal Financial Officer & Principal Accounting Officer Mr. Sergio MirallesExecutive VP & Chief Information OfficerMr. Jason KarkusPresident of Nebula GenomicsMr. Kamal ObbadSenior VP and Director of Sales & Marketing - Nebula GenomicsMore ExecutivesKey CompetitorsAbeona TherapeuticsNASDAQ:ABEOPMV PharmaceuticalsNASDAQ:PMVPGeneluxNASDAQ:GNLXAllakosNASDAQ:ALLKDiaMedica TherapeuticsNASDAQ:DMACView All CompetitorsInstitutional OwnershipTower Research Capital LLC TRCBought 5,026 shares on 2/13/2024Ownership: 0.083%Simplex Trading LLCSold 500 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions PRPH Stock Analysis - Frequently Asked Questions Should I buy or sell ProPhase Labs stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProPhase Labs in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PRPH shares. View PRPH analyst ratings or view top-rated stocks. What is ProPhase Labs' stock price target for 2024? 1 analysts have issued 1-year price targets for ProPhase Labs' stock. Their PRPH share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 117.4% from the stock's current price. View analysts price targets for PRPH or view top-rated stocks among Wall Street analysts. How have PRPH shares performed in 2024? ProPhase Labs' stock was trading at $4.52 at the beginning of the year. Since then, PRPH stock has increased by 11.9% and is now trading at $5.06. View the best growth stocks for 2024 here. When is ProPhase Labs' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PRPH earnings forecast. How were ProPhase Labs' earnings last quarter? ProPhase Labs, Inc. (NASDAQ:PRPH) announced its quarterly earnings data on Thursday, March, 28th. The company reported ($0.51) earnings per share (EPS) for the quarter. The business had revenue of $3.50 million for the quarter, compared to analysts' expectations of $10.71 million. ProPhase Labs had a negative net margin of 37.81% and a negative trailing twelve-month return on equity of 29.83%. What is Ted Karkus' approval rating as ProPhase Labs' CEO? 2 employees have rated ProPhase Labs Chief Executive Officer Ted Karkus on Glassdoor.com. Ted Karkus has an approval rating of 100% among the company's employees. This puts Ted Karkus in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of ProPhase Labs own? Based on aggregate information from My MarketBeat watchlists, some companies that other ProPhase Labs investors own include VIVUS (VVUS), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Fulcrum Therapeutics (FULC), Novus Therapeutics (NVUS), Onconova Therapeutics (ONTX) and Recro Pharma (REPH). How do I buy shares of ProPhase Labs? Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRPH) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
